Athira pharma presents data from act-ad phase 2 proof-of-concept clinical study of fosgonimeton in mild-to-moderate alzheimer's patients at the alzheimer's association international conference 2022

Additional data showed numerical improvement in activities of daily living (adcs-adl23), a protocoled secondary endpoint and a functional measure of independence

ATHA Ratings Summary

ATHA Quant Ranking